BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 9202126)

  • 21. A mutant form of JAB/SOCS1 augments the cytokine-induced JAK/STAT pathway by accelerating degradation of wild-type JAB/CIS family proteins through the SOCS-box.
    Hanada T; Yoshida T; Kinjyo I; Minoguchi S; Yasukawa H; Kato S; Mimata H; Nomura Y; Seki Y; Kubo M; Yoshimura A
    J Biol Chem; 2001 Nov; 276(44):40746-54. PubMed ID: 11522790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endoplasmic reticulum stress prolongs GH-induced Janus kinase (JAK2)/signal transducer and activator of transcription (STAT5) signaling pathway.
    Flores-Morales A; Fernández L; Rico-Bautista E; Umana A; Negrín C; Zhang JG; Norstedt G
    Mol Endocrinol; 2001 Sep; 15(9):1471-83. PubMed ID: 11518796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dominant negative variants of the SHP-2 tyrosine phosphatase inhibit prolactin activation of Jak2 (janus kinase 2) and induction of Stat5 (signal transducer and activator of transcription 5)-dependent transcription.
    Berchtold S; Volarevic S; Moriggl R; Mercep M; Groner B
    Mol Endocrinol; 1998 Apr; 12(4):556-67. PubMed ID: 9544991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppressor of cytokine signaling 1/JAB and suppressor of cytokine signaling 3/cytokine-inducible SH2 containing protein 3 negatively regulate the signal transducers and activators of transcription signaling pathway in normal human epidermal keratinocytes.
    Yamasaki K; Hanakawa Y; Tokumaru S; Shirakata Y; Sayama K; Hanada T; Yoshimura A; Hashimoto K
    J Invest Dermatol; 2003 Apr; 120(4):571-80. PubMed ID: 12648219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling.
    Lejeune D; Demoulin JB; Renauld JC
    Biochem J; 2001 Jan; 353(Pt 1):109-116. PubMed ID: 11115404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction.
    Nicholson SE; Willson TA; Farley A; Starr R; Zhang JG; Baca M; Alexander WS; Metcalf D; Hilton DJ; Nicola NA
    EMBO J; 1999 Jan; 18(2):375-85. PubMed ID: 9889194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Negative regulation of cytokine signaling pathways.
    Yasukawa H; Sasaki A; Yoshimura A
    Annu Rev Immunol; 2000; 18():143-64. PubMed ID: 10837055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SOCS-1, -2, -3: selective targets and functions downstream of the prolactin receptor.
    Tomic S; Chughtai N; Ali S
    Mol Cell Endocrinol; 1999 Dec; 158(1-2):45-54. PubMed ID: 10630404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of Janus kinase 2 by cisplatin in cancer cells.
    Song H; Sondak VK; Barber DL; Reid TJ; Lin J
    Int J Oncol; 2004 Apr; 24(4):1017-26. PubMed ID: 15010843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH.
    Smit LS; Meyer DJ; Billestrup N; Norstedt G; Schwartz J; Carter-Su C
    Mol Endocrinol; 1996 May; 10(5):519-33. PubMed ID: 8732683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl.
    Wakioka T; Sasaki A; Mitsui K; Yokouchi M; Inoue A; Komiya S; Yoshimura A
    Leukemia; 1999 May; 13(5):760-7. PubMed ID: 10374881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppressors of cytokine signalling: SOCS.
    Larsen L; Röpke C
    APMIS; 2002 Dec; 110(12):833-44. PubMed ID: 12645661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms.
    Ram PA; Waxman DJ
    J Biol Chem; 1999 Dec; 274(50):35553-61. PubMed ID: 10585430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling.
    Irie-Sasaki J; Sasaki T; Matsumoto W; Opavsky A; Cheng M; Welstead G; Griffiths E; Krawczyk C; Richardson CD; Aitken K; Iscove N; Koretzky G; Johnson P; Liu P; Rothstein DM; Penninger JM
    Nature; 2001 Jan; 409(6818):349-54. PubMed ID: 11201744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia.
    Kim HY; Park EJ; Joe EH; Jou I
    J Immunol; 2003 Dec; 171(11):6072-9. PubMed ID: 14634121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of growth hormone (GH) Janus tyrosine kinase 2/signal transducer and activator of transcription 5 signaling pathway in transgenic mice overexpressing bovine GH.
    Miquet JG; Sotelo AI; Bartke A; Turyn D
    Endocrinology; 2004 Jun; 145(6):2824-32. PubMed ID: 15016718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CIS1 interacts with the Y532 of the prolactin receptor and suppresses prolactin-dependent STAT5 activation.
    Endo T; Sasaki A; Minoguchi M; Joo A; Yoshimura A
    J Biochem; 2003 Jan; 133(1):109-13. PubMed ID: 12761205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinase activation through dimerization by human SH2-B.
    Nishi M; Werner ED; Oh BC; Frantz JD; Dhe-Paganon S; Hansen L; Lee J; Shoelson SE
    Mol Cell Biol; 2005 Apr; 25(7):2607-21. PubMed ID: 15767667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CIS/JAB family: novel negative regulators of JAK signaling pathways.
    Yoshimura A
    Leukemia; 1998 Dec; 12(12):1851-7. PubMed ID: 9844915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.
    Bousquet C; Susini C; Melmed S
    J Clin Invest; 1999 Nov; 104(9):1277-85. PubMed ID: 10545526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.